A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

Paused · Phase 2 · Has a placebo group

Conditions studied: Fragile X Syndrome

In brief

The study will consist of a Screening period (up to 14 days), a Treatment period, and a Follow-Up period. Sixteen subjects will be enrolled into two sequential dose cohorts - 10 or 30 mg (or matching placebo) across four study centers.

Key facts

Study ID
NCT01325740
Run by
Seaside Therapeutics, Inc.
People needed
16
Starts
2011-05-01
Expected to finish
2013-09-01
Last updated by the study team
2012-12-20

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.